BRIDGEBIO PHARMA INC (BBIO) Stock News
NASDAQ:BBIO - Nasdaq - US10806X1028 - Common Stock - Currency: USD
BBIO Latest News, Press Relases and Analysis
Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan
Cytokinetics, Incorporated (NASDAQ:CYTK) is one of the 13 Biotech Stocks with Huge Upside Potential. Tessa Romero, an analyst at JPMorgan, has maintained her Overweight rating on Cytokinetics, Incorporated (NASDAQ:CYTK) but reduced the firm’s price objective from $71 to $53. Aficamten’s revised revenue projections, which anticipate a slower launch trajectory, are the basis for the modification. […]
NewAmsterdam Pharma Company N.V. (NAMS) Initiated with a Buy at Stifel
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is one of the 13 Biotech Stocks with Huge Upside Potential. It is now under Stifel’s coverage, with a buy rating and a $44 price target. According to the firm, NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a distinct late-stage cardiovascular company with a short-term trajectory toward regulatory filings. Its core […]
BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 13 Biotech Stocks with Huge Upside Potential. In a recent report, Raghuram Selvaraju, an expert at H.C. Wainwright, raised the price target for BridgeBio Pharma, Inc. (NASDAQ:BBIO) from $53 to $56 and kept the stock’s buy rating. Positive momentum for the company is proven by the fast […]
Merck’s Cholesterol Medication Achieves Primary Endpoint in Two Trials
Merck & Co., Inc. (NYSE:MRK) is one of the best Dow stocks to invest in. On June 9, the company announced that its drug, enlicitide decanoate, achieved its primary goal of lowering a specific type of cholesterol in two late-stage clinical trials. The medication is being studied as a potential treatment for hyperlipidemia, a condition […]
BridgeBio price target raised to $42 from $37 at BMO Capital
BMO Capital raised the firm’s price target on BridgeBio (BBIO) to $42 from $37 and keeps a Market Perform rating on the shares. The firm anticipates Attruby’s U.S. sales in Q2 to be $77M-$89M, reflecting 110%-145% sequential growth and 20%-40% revenues above consensus, helping to drive 5%-15% upside in BridgeBio shares, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-p
Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of...
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation
The phase I study evaluates BAYRY's investigational GIRK4 inhibitor, BAY 3670549, for the treatment of patients with atrial fibrillation.
Home Depot Shrugs Tariff Risk and Delivers Solid Q1 Results, Reiterates Guidance
The Home Depot, Inc. (NYSE:HD) is capitalizing on customers tackling smaller projects. That’s one of the company’s strategies as it navigates a challenging macroenvironment worsened by the US-China tariff war. That was evident after the home improvement retailer delivered solid first-quarter results on Tuesday. Net sales were up 9% year over year to $39.86 billion […]
Leadership Transition at Schrödinger: Richie Jain Named CFO
On May 20, Schrödinger, Inc. (NASDAQ:SDGR) announced the departure of Chief Financial Officer Geoffrey Porges, MBBS., who is stepping down to pursue other opportunities. Richie Jain, previously Senior Vice President of Strategic Finance and Head of Corporate and Business Development, will succeed him. Dr. Porges will continue as an advisor until June 6, 2025, to […]
Workday Introduces Illuminate AI Agents to Revolutionize Workflows
On May 19, Workday Inc. (NASDAQ:WDAY) unveiled Illuminate AI Agents, a new generation of AI-powered tools aimed at accelerating hiring, enhancing frontline worker experiences, and streamlining financial processes. Designed to boost productivity, these agents integrate Workday’s responsible AI foundation and extensive HR and finance expertise. “The key to unlocking real business value with AI is […]
BMO Capital Maintains Cautious Outlook on Novo Nordisk Amid CEO Transition
On May 19, BMO Capital Markets reaffirmed its “Market Perform” rating and $64.00 price target for Novo Nordisk A/S (NYSE:NVO) following the announcement of a CEO transition. Analysts view the leadership change as a response to competitive pressures and shareholder demands, but warn that without a strategic shift, challenges may persist. On May 16, Novo […]
CrowdStrike Strengthens AI Security with NVIDIA Enterprise AI Factory Integration
On May 19, CrowdStrike Holdings, Inc. (NASDAQ:CRWD) announced its integration into the NVIDIA Enterprise AI Factory validated design, enabling enterprises to protect AI infrastructure, systems, and models as they scale AI adoption. With NVIDIA Blackwell infrastructure, this validated design provides a full-stack AI ecosystem—covering data ingestion, model training, deployment, and runtime use—to help businesses harness […]
Are Medical Stocks Lagging Alignment Healthcare (ALHC) This Year?
Here is how Alignment Healthcare (ALHC) and BridgeBio Pharma (BBIO) have performed compared to their sector so far this year.
Mentions: ALHC
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
- In a post-hoc analysis of ATTRibute-CM, acoramidis reduced the annual frequency of CVH due to AF/AFL by 43% compared to placebo and reduced the incidence...
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
- For each 5-mg/dL increase in serum TTR level within 28 days of starting treatment, the relative risk reduction of mortality was up to 31.6% through Month...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical...
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
UK financial regulator proposes revisions to insurance rule book
The regulator aims to reduce costs and improve access to insurance, while ensuring “appropriate” protection levels are maintained.
Why BridgeBio Pharma, Inc. (BBIO) Declined on Tuesday
We recently published an article titled Massive Sell-Offs Just Hit These 10 Stocks Today. In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other stocks. Wall Street’s main indices finished mixed on Tuesday, as investors digested the country’s latest inflation figures, which came out lower than […]
American Eagle Outfitters Forecasts Quarterly Operating Loss, Withdraws Fiscal 2025 Outlook
American Eagle Outfitters (AEO) shares fell early Wednesday as the clothing retailer said it expects
Wall Street Analysts Believe BridgeBio Pharma (BBIO) Could Rally 63.87%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 63.9% in BridgeBio Pharma (BBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
- ATTRibute-CM, BridgeBio’s Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or...
First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC
PALO ALTO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical...
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025
PALO ALTO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical...
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk
Alnylam analysts highlight Amvuttra's strong launch positioning and limited tariff risk, with bullish ratings maintained despite early launch volatility.
Mentions: ALNY
Is Identiv, Inc. (INVE) the Best Cybersecurity Stock to Invest in Under $20?
We recently published a list of 10 Best Cybersecurity Stocks to Invest in Under $20. In this article, we are going to take a look at where Identiv, Inc. (NASDAQ:INVE) stands against other best cybersecurity stocks to invest in under $20. The cybersecurity sector is at a tipping point, driven by growing cyber threats, breakthrough […]
Is Telos Corporation (TLS) the Best Cybersecurity Stock to Invest in Under $20?
We recently published a list of 10 Best Cybersecurity Stocks to Invest in Under $20. In this article, we are going to take a look at where Telos Corporation (NASDAQ:TLS) stands against other best cybersecurity stocks to invest in under $20. The cybersecurity sector is at a tipping point, driven by growing cyber threats, breakthrough […]
How to manage a semi-truck business loan
Learn ways to manage your semi-truck loan and what to do if you can’t make payments.
Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday
We recently published an article titled Excellent Earnings Propelled Prices of These 10 Firms. In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other stocks that soared on Wednesday. The stock market finished Wednesday’s trading on a lackluster note, with the three major indices finishing mixed, as […]
Why Mondelez International, Inc. (MDLZ) Surged on Wednesday
We recently published an article titled Excellent Earnings Propelled Prices of These 10 Firms. In this article, we are going to take a look at where Mondelez International, Inc. (NASDAQ:MDLZ) stands against the other stocks that soared on Wednesday. The stock market finished Wednesday’s trading on a lackluster note, with the three major indices finishing mixed, as […]
McEwen Mining initiated with an Outperform at National Bank
National Bank initiated coverage of McEwen Mining (MUX) with an Outperform rating and C$20 price target The company’s Los Azules copper mega-project shows mega-rerate potential, though the stock’s The valuation disparity is largely explained by the Los Azules project stage, time until start of development, financing and construction de-risking, and the constraints faced by a junior to clear these value impediments, the analyst tells investors in a research note. Published first on TheFly – the u
BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 12% and 86.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: ASMB